SCHEMBL20504348

SCHEMBL20504348

CCC(CN)c1ccc(C(=O)OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.54
MAPT P10636 3/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
STAT3 P40763 1/20 0.48
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA7 P43166 1/20 0.47
DPP4 P27487 2/20 0.46
HPGD P15428 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14551475 1.00 LOXL2 (0.54) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL13508620 0.90 HDAC8 (0.62) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL14553477 0.82 HDAC8 (0.50) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL29110956 0.82 HDAC8 (0.50) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL21656844 0.82 HDAC8 (0.54) LOXL2MAPTHDAC8HDAC6CA1
SCHEMBL5068172 0.82 FFAR1 (0.55) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL5068169 0.82 FFAR1 (0.55) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL25334148 0.81 HDAC8 (0.49) LOXL2MAPTHDAC8HDAC6STAT3
SCHEMBL15943178 0.80 LOXL2 (0.47) LOXL2MAPTCA1CA2CA12
SCHEMBL14551394 0.80 LOXL2 (0.47) LOXL2MAPTSTAT3CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108463458-B Modulators of ROR-gamma 生命医药有限责任公司 2022-02-01 CN disclosed
WO-2022008383-A1 ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-01-13 WO disclosed
US-11008340-B2 Modulators of ROR-gamma VITAE PHARMACEUTICALS, LLC (US) 2021-05-18 US disclosed
US-11008340-B2 Modulators of ROR-gamma VITAE PHARMACEUTICALS, LLC (US) 2021-05-18 US disclosed
EP-3377482-B1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS LLC (US) 2021-05-12 EP disclosed
US-20190322687-A1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS, LLC (US) 2019-10-24 US disclosed
US-20190322687-A1 MODULATORS OF ROR-GAMMA VITAE PHARMACEUTICALS, LLC (US) 2019-10-24 US disclosed
EP-3377482-A1 MODULATORS OF ROR-GAMMA Vitae Pharmaceuticals, Inc. (US) 2018-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008340-B2 Modulators of ROR-gamma RORC, RORB, RORA LOXL2 3551/4885MAPT 3682/4885HDAC8 870/4885
US-20190322687-A1 MODULATORS OF ROR-GAMMA RORC, RORB, RORA LOXL2 3551/4885MAPT 3682/4885HDAC8 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.